Menu Search
Equities

Marksans Pharma Ltd

MARKSANS:NSI

Marksans Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)308.65
  • Today's Change0.25 / 0.08%
  • Shares traded2.95m
  • 1 Year change+120.94%
  • Beta1.2965
Data delayed at least 15 minutes, as of Nov 22 2024 10:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Marksans Pharma Ltd grew revenues 17.56% from 18.52bn to 21.77bn while net income improved 17.80% from 2.66bn to 3.14bn.
Gross margin55.32%
Net profit margin14.61%
Operating margin17.82%
Return on assets13.30%
Return on equity16.69%
Return on investment15.78%
More ▼

Cash flow in INRView more

In 2024, Marksans Pharma Ltd increased its cash reserves by 5.45%, or 208.40m. The company earned 2.30bn from its operations for a Cash Flow Margin of 10.58%. In addition the company used 1.41bn on investing activities and also paid 687.27m in financing cash flows.
Cash flow per share9.51
Price/Cash flow per share32.55
Book value per share50.34
Tangible book value per share47.87
More ▼

Balance sheet in INRView more

Marksans Pharma Ltd has a Debt to Total Capital ratio of 7.92%, a higher figure than the previous year's 3.26%.
Current ratio4.68
Quick ratio2.97
Total debt/total equity0.0869
Total debt/total capital0.0792
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 20.00% and 7.98%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg)0.51%
Div growth rate (5 year)64.38%
Payout ratio (TTM)6.53%
EPS growth(5 years)29.95
EPS (TTM) vs
TTM 1 year ago		13.21
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.